Search results
Results from the WOW.Com Content Network
With Johnson & Johnson behind it, and with an additional $100 million invested in its development, the Palmaz stent was approved for use in peripheral arteries in 1991, followed by approval for use in coronary arteries in 1994; Johnson & Johnson quickly captured 90 percent of the market for stents and bought the patent outright from Palmaz ...
Stent technology improved rapidly, and in 1989 the Palmaz-Schatz balloon-expandable intracoronary stent was developed. [24] [25] Initial results with the Palmaz-Schatz stents were excellent when compared to balloon angioplasty, with a significantly lower incidence of abrupt closure and peri-procedure heart attack. [26]
This is a list of products and services provided by Johnson & Johnson (J&J). Medical technologies In ...
Though several doctors have been credited with the creation of the stent, the first FDA-approved stent in the U.S. was created by Richard Schatz and coworkers. Named the Palmaz-Schatz (Johnson & Johnson), it was developed in 1987. [21] To further reduce the incidence of restenosis, the drug-eluting stent was introduced in 2003. [22]
Fred Kobylarz, MD, is co-director of the Center for Healthy Aging at Rutgers Robert Wood Johnson Medical School. ‘Sundowning’ is a term that refers to behavior changes in people with dementia ...
Johnson & Johnson was founded in 1886 by three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, selling ready-to-use sterile surgical dressings. In 2023, the company split-off its consumer healthcare business sector into a new publicly traded company, Kenvue .
The United States Food and Drugs Administration is warning pet owners about a common medication given to pets to treat arthritis. The F.D.A. now says that the drug Librela may be associated with ...
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. More and more treatment options are becoming available for obesity and overweight. This includes type 2 diabetes drugs and weight ...